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TO THE EDITOR
Chronic plaque psoriasis is a common,
genetic, immune-mediated skin disor-
der that can be dichotomized according
to age of onset: early-onset psoriasis
(EOP; type 1, onset before 40 years of
age, B75% of subjects) and late-onset
psoriasis (LOP; type 2, onset over 40
years of age, B25% of subjects;
Henseler and Christophers, 1985).
Recently, genome-wide association
studies (GWAS) have made significant
strides in elucidating the genetic basis
of EOP with a total of 36 loci now
identified (He´bert et al., 2012; Tsoi
et al., 2012). In comparison, there are
only two genetic studies speci-
fically in LOP: one found no
association with HLA-Cw6, the major
genetic locus associated with EOP
(Allen et al., 2004; Gudjonsson et al.,
2006) while a second separate study
found a nominal association with a
variant (rs16944) mapping to the IL1B
promoter region (Reich et al., 2002).
Inflammatory cytokines, such as IL-1-
beta (IL1b) and tumor necrosis factor-
alpha (TNF-a), have a well-documented
role in the pathogenesis of psoriasis
(Griffiths and Barker, 2007; Nestle
et al., 2009). They are important
stimuli of the migration of epidermal
Langerhans cells (LC) and plasmacytoid
dendritic cells from the skin to draining
lymph nodes where they engage with T
cells. It has been shown that LC
migration in response to these cyto-
kines differs between EOP and LOP
(Cumberbatch et al., 2006; Shaw et al.,
2010). This combination of genetic and
immunological observations implicating
a role for IL1b in mechanisms under-
lying LOP led us to investigate
whether genetic variation at the IL1B
gene is associated with psoriasis. We
compared association of polymorphisms
from IL1B between cohorts of EOP and
LOP patients.
Patients of Caucasian descent with
chronic plaque psoriasis were recruited
from UK Dermatology Centres at Salford
Royal NHS Foundation Trust, Manche-
ster, UK; Guy’s Hospital, London and
the National Hospital for Rheumatic
Diseases, Bath, UK. The study adheres
to the Declaration of Helsinki Princi-
ples, was approved by the relevant local
research ethics committees, and all
subjects provided written informed
consent.Accepted article preview online 20 September 2013; published online 12 December 2013
Abbreviations: CI, confidence interval; EOP, early-onset psoriasis; IL1b, IL-1-beta; LC, Langerhans cell;
LOP, late-onset psoriasis; OR, odds ratio; SNP, single-nucleotide polymorphism; TNF-a, tumor necrosis
factor-alpha
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Patients were divided into two sub-
types for analysis: EOP (onseto40 years
of age) and LOP (onset X40 years). A
secondary analysis was conducted,
omitting samples with onset between
30 and 50 years of age.
Psoriasis samples were genotyped
using the Sequenom MassArray platform
with iPLEX Gold chemistry (Sequenom,
Table 1. Association of SNPs in IL1b with late-onset psoriasis
Overall (n¼595; rs16944¼ 615)
Onset X 50 years
(n¼271; rs16944¼ 284)
Controls
(n¼4,770)
SNP Chr
Minor
allele MAF P-value OR (95% CI) MAF P-value OR (95% CI) MAF
Major
allele
rs3783516 2 T 0.400 0.900 0.990 (0.875–1.120) 0.420 0.366 1.085 (0.910–1.294) 0.400 C
rs3783512 2 T 0.325 0.071 1.127 (0.991–1.282) 0.328 0.163 1.144 (0.951–1.376) 0.300 C
rs11687624 2 C 0.472 1.53 103 1.218 (1.079–1.374) 0.489 3.14 10 3 1.301 (1.094–1.548) 0.424 T
rs6716046 2 C 0.236 0.202 0.911 (0.791–1.050) 0.242 0.576 0.940 (0.768–1.150) 0.253 T
rs11680809 2 C 0.436 0.687 0.974 (0.863–1.100) 0.454 0.625 1.047 (0.880–1.246) 0.443 A
rs12469600 2 C 0.238 0.139 0.898 (0.780–1.034) 0.219 0.043 0.803 (0.652–0.990) 0.258 T
rs4849124 2 A 0.308 0.501 1.046 (0.918–1.193) 0.291 0.735 0.965 (0.797–1.168) 0.298 G
rs2853550 2 A 0.104 8.72 103 1.318 (1.078–1.610) 0.119 2.91 10 3 1.531 (1.167–2.008) 0.081 G
rs1143643 2 T 0.321 5.25 103 0.833 (0.732–0.947) 0.323 0.066 0.840 (0.698–1.011) 0.362 C
rs4447608 2 T 0.439 0.109 0.905 (0.801–1.021) 0.434 0.170 0.883 (0.742–1.052) 0.464 C
rs6745746 2 A 0.439 0.102 0.902 (0.799–1.019) 0.434 0.170 0.884 (0.742–1.053) 0.464 G
rs4334503 2 T 0.202 0.472 0.943 (0.811–1.096) 0.191 0.278 0.880 (0.706–1.097) 0.211 C
rs2708919 2 T 0.481 0.735 1.023 (0.907–1.154) 0.476 0.965 1.004 (0.844–1.194) 0.475 C
rs2723154 2 T 0.143 0.634 0.957 (0.806–1.137) 0.148 1.000 0.994 (0.779–1.269) 0.148 C
rs2708960 2 T 0.084 0.457 1.088 (0.875–1.353) 0.083 0.622 1.073 (0.784–1.470) 0.078 C
rs16944 2 A 0.360 0.026 1.153 (1.018–1.305) 0.387 3.85 10 3 1.295 (1.088–1.541) 0.328 G
Abbreviations: Chr, chromosome; CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.
Table 2. Association of SNPs in IL1b with early-onset psoriasis
Overall (n¼ 1,137; rs16944¼1,216
Onset o 30 years
(n¼ 863; rs16944¼927)
Controls
(n¼ 4,770)
SNP Chr
Minor
allele MAF P-value OR (95% CI) MAF P-value OR (95% CI) MAF
Major
allele
rs3783516 2 T 0.412 0.329 1.048 (0.955–1.150) 0.408 0.575 1.031 (0.929–1.145) 0.400 C
rs3783512 2 T 0.315 0.162 1.074 (0.973–1.186) 0.317 0.154 1.084 (0.971–1.211) 0.300 C
rs11687624 2 C 0.442 0.114 1.077 (0.983–1.182) 0.445 0.101 1.091 (0.984–1.209) 0.424 T
rs6716046 2 C 0.267 0.181 1.074 (0.968–1.191) 0.263 0.384 1.054 (0.938–1.185) 0.253 T
rs11680809 2 C 0.449 0.557 1.028 (0.938–1.127) 0.447 0.752 1.017 (0.917–1.128) 0.443 A
rs12469600 2 C 0.236 0.030 0.888 (0.798–0.988) 0.236 0.051 0.886 (0.786–1.000) 0.258 T
rs4849124 2 A 0.289 0.412 0.957 (0.865–1.059) 0.292 0.605 0.969 (0.865–1.085) 0.298 G
rs2853550 2 A 0.093 0.057 1.171 (0.999–1.374) 0.094 0.064 1.186 (0.992–1.416) 0.081 G
rs1143643 2 T 0.358 0.698 0.980 (0.891–1.078) 0.354 0.531 0.965 (0.867–1.075) 0.362 C
rs4447608 2 T 0.463 0.888 0.993 (0.906–1.089) 0.461 0.793 0.985 (0.889–1.092) 0.464 C
rs6745746 2 A 0.462 0.852 0.991 (0.904–1.086) 0.459 0.733 0.982 (0.886–1.088) 0.464 G
rs4334503 2 T 0.203 0.372 0.948 (0.846–1.062) 0.200 0.317 0.935 (0.822–1.062) 0.211 C
rs2708919 2 T 0.470 0.674 0.980 (0.894–1.074) 0.472 0.793 0.986 (0.890–1.093) 0.475 C
rs2723154 2 T 0.152 0.670 1.028 (0.905–1.168) 0.152 0.713 1.028 (0.891–1.186) 0.148 C
rs2708960 2 T 0.079 0.862 1.015 (0.856–1.203) 0.081 0.661 1.041 (0.862–1.257) 0.078 C
rs16944 2 A 0.331 0.753 1.015 (0.924–1.116) 0.341 0.269 1.062 (0.956–1.180) 0.328 G
Abbreviations: Chr, chromosome; CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.
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San Diego, CA) and Taqman (Applied
Biosystems, Foster City CA) (rs16944)
according to the manufacturer’s instruc-
tions. Genotypes for control samples
were imputed from GWAS data obtai-
ned from the Wellcome Trust Case
Control Consortium (www.wtccc.org.
uk; Wellcome Trust Case Control
Consortium, 2007) using IMPUTE v2
(Howie et al., 2009).
Samples and markers were subjected
to quality control and association
analysis (Cochran–Armitage test for
trend with Fisher’s exact test) using
PLINK (v1.07) (Purcell et al., 2007).
Any sample or marker with a call rate
o90%, a minor allele frequency o5%,
or Hardy–Weinberg P-valueo1104
were removed. Finally, a Bonferroni
correction for multiple testing was
applied giving a significance threshold
of Po3.12103, except for rs16944,
which was considered significant at
Po0.05 because of prior evidence for
association.
A total of 1,906 psoriasis patients
were recruited to the study; 1,263 were
EOP patients (mean age of onset 20.3
years, SD 9.7 years) and 643 were LOP
patients (mean age of onset 50.7 years,
SD 9.2 years). Following quality control,
data for 16 tagging single-nucleotide
polymorphisms (SNPs) were available
within the IL1B gene region.
The previously published association
at rs16944 (Reich et al., 2002) was
replicated in this study (P¼ 0.03, odds
ratio (OR)¼1.15, 95% confidence in-
terval (CI)¼1.02–1.31). Furthermore,
rs11687624 (P¼1.53103, OR¼
1.22, 95% CI¼ 1.08–1.37), was found
to be associated with LOP at Bonferroni
significance (Table 1). SNP rs11687624
is located in the intergenic region
between IL1B and IL1A. Another two
SNPs, rs1143643 and rs2853550, show-
ed nominal association. When the ana-
lysis was performed on those with age of
psoriasis onset over 50 years rs2853550
(PX50¼ 2.9110 3, OR¼1.53, 95%
CI¼ 1.17–2.01) became significantly
associated with LOP. Marker
rs11687624, although losing Bonferroni
significance, retained a nominal asso-
ciation that was very close to the thresh-
old. SNP rs16944 (PX50¼3.85103,
OR¼1.30, 95% CI¼ 1.09–1.54)
remained significant at Po0.05.
None of the SNPs analyzed in the
study were significantly associated with
EOP (Table 2). One SNP, rs12469600
(P¼ 0.03, OR¼0.89, 95% CI¼0.80–
0.99) showed nominal association,
however, this was eliminated when
samples with psoriasis onset over 30
years were removed.
It should be noted that the associa-
tions reported in this study have not
been identified in previous GWAS
because of the predominant, if not
exclusive use of EOP samples thereby
diluting any associations with LOP.
A drawback of the study is the uncer-
tainty that exists surrounding the dichot-
omy of samples into EOP and LOP.
A ‘‘gray area’’ exists with disease onset
between 30 and 50 years of age
where diagnosis is uncertain which has
implications for the study in terms of
possible false positives. However, we
have attempted to counteract this by
undertaking a separate analysis remov-
ing samples with psoriasis onset
between 30 and 50 years. In LOP, the
strength of association increased for two
SNPs, rs16944 and rs2853550, which
reached the Bonferroni threshold for
claims of significance despite the
reduced sample size. These findings
support the association of IL1B with
LOP but not EOP.
In conclusion, this is the largest
genetic study of LOP to date and has
identified IL1B as being significantly and
exclusively associated. These results
require replication and consideration
should be given to the possibility that
the disease-causing mutations may not
reside within IL1B. Therefore, future
work should focus first on fine mapping
to find the causative mutations and
second on carrying out functional work
to establish how the polymorphisms
contribute to disease onset at a biologi-
cal level. Further studies are needed to
uncover fully the genetics underpinning
LOP and the extent to which they are
separable from EOP.
CONFLICT OF INTEREST
RBW has acted as a consultant and/or speaker for
Abbott (now AbbVie). CEMG has acted as con-
sultant for and/or received research grants from
Abbott (now AbbVie). JNWNB has acted as a
consultant to Abbott (now AbbVie). AB has acted
as consultant for and/or received research grants
from Abbott (now AbbVie).
ACKNOWLEDGMENTS
HLH is funded by a PhD studentship from Abbott
(now AbbVie). The research was supported by the
National Institute for Health Research (NIHR)
Biomedical Research Centre based at Guy’s
and St Thomas’ NHS Foundation Trust and King’s
College London. The views expressed are those of
the authors and not necessarily those of the NHS,
the NIHR, or the Department of Health. RBW is an
NIHR Clinical Senior Lecturer. CEMG is an NIHR
senior investigator. JB and AB are funded by
Arthritis Research UK (grant ref. 20385).
Harry L. He´bert1,2, John Bowes2,
Rhodri L. Smith2, Neil J. McHugh3,
Jonathan N.W.N. Barker4,
Christopher E.M. Griffiths1,
Anne Barton2,5 and Richard B. Warren1
1The Dermatology Centre, Salford Royal NHS
Foundation Trust, University of Manchester,
Manchester Academic Health Science Centre,
Manchester, UK; 2Arthritis Research UK Centre
for Genetics and Genomics, University of
Manchester, Manchester Academic Health
Science Centre, Manchester, UK; 3Royal
National Hospital for Rheumatic Diseases and
Department Pharmacy and Pharmacology,
University of Bath, Bath, UK; 4Division of
Genetics and Molecular Medicine, King’s
College London School of Medicine, King’s
College London, London, UK and 5NIHR
Manchester Musculoskeletal Biomedical
Research Unit, Central Manchester Foundation
Trust, Manchester Academic Health Science
Centre, Manchester, UK
E-mail: richard.warren@manchester.ac.uk
REFERENCES
Allen MH, Ameen H, Veal C et al. (2004) The
major psoriasis susceptibility locus PSORS1 is
not a risk factor for late-onset psoriasis.
J Invest Dermatol 124:103–6
Cumberbatch M, Singh M, Dearman RJ et al.
(2006) Impaired Langerhans cell migration in
psoriasis. J Exp Med 203:953–60
Griffiths CE, Barker JN (2007) Pathogenesis and
clinical features of psoriasis. Lancet 370:263–71
Gudjonsson JE, Karason A, Runarsdottir EH et al.
(2006) Distinct clinical differences between
HLA-Cw*0602 positive and negative psoriasis
patients - an analysis of 1019 HLA-C- and HLA-
B-typed patients. J Invest Dermatol 126:740–5
He´bert HL, Ali FR, Bowes J et al. (2012) Genetic
susceptibility to psoriasis and psoriatic arthri-
tis: implications for therapy. Br J Dermatol
166:474–82
Henseler T, Christophers E (1985) Psoriasis of early
and late onset: characterization of two types
of psoriasis vulgaris. J Am Acad Dermatol
13:450–6
Howie BN, Donnelly P, Marchini J (2009) A flexible
and accurate genotype imputation method for
the next generation of genome-wide associa-
tion studies. PLoS Genet 5:e1000529
Nestle FO, Kaplan DH, Barker J (2009) Psoriasis.
N Engl J Med 361:496–509
HL He´bert et al.
IL1B Is Associated with Late-Onset Psoriasis
www.jidonline.org 1461
Purcell S, Neale B, Todd-Brown K et al. (2007)
PLINK: a tool set for whole-genome associa-
tion and population-based linkage analyses.
Am J Hum Genet 81:559–75
Reich K, Mossner R, Konig IR et al. (2002)
Promoter polymorphisms of the genes encod-
ing tumor necrosis factor-a and interleukin-1b
are associated with different subtypes of
psoriasis characterized by early and late dis-
ease onset. J Invest Dermatol 118:155–63
Shaw FL, Cumberbatch M, Kleyn CE et al. (2010)
Langerhans cell mobilization distinguishes
between early-onset and late-onset psoriasis.
J Invest Dermatol 130:1940–2
Tsoi LC, Spain SL, Knight J et al. (2012) Identification of
15 new psoriasis susceptibility loci highlights the
role of innate immunity. Nat Genet 44:1341–8
Wellcome Trust Case Control Consortium (2007)
Genome-wide association study of 14,000
cases of seven common diseases and 3,000
shared controls. Nature 447:661–78
Dermal Clusters of Mature Dendritic Cells and T Cells Are
Associated with the CCL20/CCR6 Chemokine System in
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TO THE EDITOR
Psoriasis is a prototype for chronic
inflammatory skin disease mediated by
activated T cells showing T helper type
1 (Th1)/Th17 dominance (Di Cesare
et al., 2009). In lesional psoriasis, a
markedly increased number of prolife-
rating memory-type T cells has been
observed, suggesting their continuous
activation by lesional antigen-present-
ing cells (Bos et al., 1989; Morganroth
et al., 1991; Chang et al., 1992). In
the psoriatic dermis, populations of
mature myeloid dendritic cells (DCs)
are characterized by expressing
DC-lysosomal-associated membrane
protein (DC-LAMP/CD208), and they
characteristically aggregate together
with the infiltrating T cells mimicking
the T-cell areas of secondary lymphoid
organs (Zaba et al., 2007). These ectopic
lymphoid structures have been reported
in peripheral non-lymphoid tissues
during local infection and inflamma-
tion (Katou et al., 2000; Page et al.,
2002; Zaba et al., 2007), and are
thought to act as the nidus that
contributes to disease progression by
autoantigen presentation and activation
of T cells in situ (Carragher et al., 2008;
Weyand et al., 2001). In this regard,
knowing the molecular mechanisms
involved in the formation of dermal
aggregates of mature DCs and T cells
in psoriasis may be important for further
understanding of chronic inflammation
(Guttman-Yassky et al., 2011).
Psoriatic lesions contain abundant
epithelial CC chemokine 20 (CCL20)
and dermal CC chemokine receptor 6
(CCR6)-expressing skin-homing T cells,
which are crucial for psoriasis
pathogenesis (Homey et al., 2000;
Hedrick et al., 2009). Previous studies
have established the possible
association of the CCL20/CCR6
chemokine system with peripheral
lymphoid structures in the chronically
inflamed epithelial tissues (Page et al.,
2002). Thus, our study was aimed to
assess whether this crucial CCL20/CCR6
pair is also related to the characteristic
cellular aggregates present in chronic
psoriatic lesions, and in turn, to suggest
a potential therapeutic target for
controlling chronic inflammation.
To obtain an insight into the cellular
location of CCR6þ cells, we performed
a series of immunohistochemical stu-
dies. We found significantly greater
numbers of both CCR6þ and CCR7þ
cells with aggregate patterns in lesional
psoriatic skin (Supplementary Figure S1
online). With existing previous data
showing the association of the CCL19/
CCR7 chemokine system in psoriatic
dermal aggregates (Mitsui et al., 2012),
we sought to demonstrate the possible
existence of the CCL20/CCR6 system in
these cellular structures.
To identify the cellular distribution of
CCR6 in lesional psoriasis, we used
double-label immunofluorescence. We
found that significant numbers of dermal
HLA-DRþ or CD11cþ antigen-pre-
senting DCs and CD3þ infiltrating
T cells expressed CCR6 (Figure 1a).
Interestingly, CCR6þ dermal DCs pre-
sented an unexpected aggregate pattern,
which resembled DC-LAMPþ mature
psoriatic DCs (Zaba et al., 2007). Thus
we decided to analyze CCR6 expression
in DC-LAMPþ cells. Importantly, almost
all of the DC-LAMPþ mature DCs co-
expressed CCR6 in the psoriatic dermis
(Figure 1b). To compare the level of
CCR6 expression between immature
and mature DCs, we prepared dermal
single cell suspensions from normal
and psoriatic skin and performed
flow cytometry. We found that the
dermal CD11cþHLA-DRþDC-LAMPþ
mature DCs specifically expressed
CCR6; however, DC-LAMPDCs
were devoid of CCR6 (Figure 1c).
These results suggest that psoriatic
CCR6þ mature DCs could aggregate
with CCR6þ T cells and continuously
activate them. Thus, the CCL20/CCR6
chemokine system may be another
candidate that induces the formationAccepted article preview online 13 December 2013; published online 9 January 2014
Abbreviations: CCL20, CC chemokine 20; CCR6, CC chemokine receptor 6; DC, dendritic cell; DC-LAMP,
DC-lysosomal-associated membrane protein
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